Published in J Biol Chem on June 24, 2003
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature (2012) 4.01
Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer (2011) 3.55
The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell (2009) 2.90
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A (2009) 2.84
A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell (2007) 2.70
The tyrosine kinase network regulating mast cell activation. Immunol Rev (2009) 2.29
Structural basis for the recognition of c-Src by its inactivator Csk. Cell (2008) 1.66
A recurrent PDGFRB mutation causes familial infantile myofibromatosis. Am J Hum Genet (2013) 1.66
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res (2009) 1.42
A crystallographic snapshot of tyrosine trans-phosphorylation in action. Proc Natl Acad Sci U S A (2008) 1.25
Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br J Pharmacol (2008) 1.25
Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A (2014) 1.12
Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages. Proc Natl Acad Sci U S A (2004) 1.10
Gastrointestinal stromal tumors: past, present, and future. J Gastroenterol (2008) 1.09
Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol (2010) 1.08
Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn (2006) 1.05
Molecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2. Elife (2014) 1.01
Bioinformatics and variability in drug response: a protein structural perspective. J R Soc Interface (2012) 1.01
Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases. Nat Rev Cancer (2012) 0.99
Production of selenomethionyl-derivatized proteins in baculovirus-infected insect cells. Protein Sci (2007) 0.99
Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligase. J Biol Chem (2010) 0.98
Allosteric communication across the native and mutated KIT receptor tyrosine kinase. PLoS Comput Biol (2012) 0.94
Structural basis for the impact of phosphorylation on the activation of plant receptor-like kinase BAK1. Cell Res (2012) 0.94
Structure of the human protein kinase MPSK1 reveals an atypical activation loop architecture. Structure (2008) 0.92
Platelet-derived growth factors and their receptors: structural and functional perspectives. Biochim Biophys Acta (2012) 0.91
Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms. PLoS Comput Biol (2011) 0.91
c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations? J Clin Pathol (2004) 0.88
Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations. PLoS One (2013) 0.88
Drug binding and resistance mechanism of KIT tyrosine kinase revealed by hydrogen/deuterium exchange FTICR mass spectrometry. Protein Sci (2010) 0.88
Progenitor cell mobilization and recruitment: SDF-1, CXCR4, α4-integrin, and c-kit. Prog Mol Biol Transl Sci (2012) 0.87
Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms. Immunol Allergy Clin North Am (2014) 0.86
Update on imatinib for gastrointestinal stromal tumors: duration of treatment. Onco Targets Ther (2013) 0.85
c-kit and its related genes in spermatogonial differentiation. Spermatogenesis (2011) 0.85
Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220). PLoS One (2015) 0.84
Consequences of replacing EGFR juxtamembrane domain with an unstructured sequence. Sci Rep (2012) 0.84
Insights into the characteristics of mammalian cardiomyocyte terminal differentiation shown through the study of mice with a dysfunctional c-kit. Pediatr Cardiol (2009) 0.83
KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. Leuk Res (2007) 0.83
Structure, domain organization, and different conformational states of stem cell factor-induced intact KIT dimers. Proc Natl Acad Sci U S A (2014) 0.83
Structural and functional properties of platelet-derived growth factor and stem cell factor receptors. Cold Spring Harb Perspect Biol (2013) 0.82
Pigment pattern formation in the guppy, Poecilia reticulata, involves the Kita and Csf1ra receptor tyrosine kinases. Genetics (2013) 0.82
Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region. Proc Natl Acad Sci U S A (2013) 0.81
Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication. PLoS One (2014) 0.80
Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors. Bioorg Med Chem Lett (2012) 0.79
Phosphorylation of the activation loop tyrosine 823 in c-Kit is crucial for cell survival and proliferation. J Biol Chem (2013) 0.79
Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivity. PLoS Comput Biol (2014) 0.79
Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents. Bioorg Med Chem (2010) 0.79
KIT is required for hepatic function during mouse post-natal development. BMC Dev Biol (2007) 0.79
Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models. Transl Oncol (2015) 0.77
The strength and cooperativity of KIT ectodomain contacts determine normal ligand-dependent stimulation or oncogenic activation in cancer. Mol Cell (2014) 0.77
Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinases. Sci Signal (2015) 0.77
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors. Oncotarget (2017) 0.76
The structural insights of stem cell factor receptor (c-Kit) interaction with tyrosine phosphatase-2 (Shp-2): an in silico analysis. BMC Res Notes (2010) 0.75
Two transmembrane dimers of the bovine papillomavirus E5 oncoprotein clamp the PDGF β receptor in an active dimeric conformation. Proc Natl Acad Sci U S A (2017) 0.75
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science (2008) 11.74
Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science (2010) 10.30
A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. Structure (2008) 6.01
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem (2004) 3.79
Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (2004) 3.31
Microscale fluorescent thermal stability assay for membrane proteins. Structure (2008) 2.95
An IAP-IAP complex inhibits apoptosis. J Biol Chem (2004) 2.82
HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J (2003) 2.47
Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol (2009) 2.39
Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem (2004) 2.05
Long non-coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival. Cancer Sci (2013) 1.88
Crystal structure of a continuous three-dimensional DNA lattice. Chem Biol (2004) 1.87
Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem (2007) 1.73
Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem (2011) 1.61
Ligand-dependent perturbation of the conformational ensemble for the GPCR β2 adrenergic receptor revealed by HDX. Structure (2011) 1.54
High-resolution crystal structures and spectroscopy of native and compound I cytochrome c peroxidase. Biochemistry (2003) 1.44
Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem (2005) 1.44
Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. Structure (2002) 1.42
Crystal structure of a human aminoacyl-tRNA synthetase cytokine. Proc Natl Acad Sci U S A (2002) 1.40
Dynamics of the beta2-adrenergic G-protein coupled receptor revealed by hydrogen-deuterium exchange. Anal Chem (2010) 1.38
Crystal structures that suggest late development of genetic code components for differentiating aromatic side chains. Proc Natl Acad Sci U S A (2003) 1.36
Conformational flexibility in the flap domains of ligand-free HIV protease. Acta Crystallogr D Biol Crystallogr (2007) 1.36
Alanyl-tRNA synthetase crystal structure and design for acceptor-stem recognition. Mol Cell (2004) 1.34
Structure of small protein B: the protein component of the tmRNA-SmpB system for ribosome rescue. EMBO J (2002) 1.31
A novel class of microbial phosphocholine-specific phospholipases C. Mol Microbiol (2002) 1.30
Fragment-based screen against HIV protease. Chem Biol Drug Des (2010) 1.26
Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci (2004) 1.23
Two conformations of a crystalline human tRNA synthetase-tRNA complex: implications for protein synthesis. EMBO J (2006) 1.21
Prediction of conformational B-cell epitopes from 3D structures by random forests with a distance-based feature. BMC Bioinformatics (2011) 1.20
High-resolution structure of the soluble, respiratory-type Rieske protein from Thermus thermophilus: analysis and comparison. Biochemistry (2003) 1.19
IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation. J Neuroinflammation (2011) 1.17
Characterization of the two catalytic domains in histone deacetylase 6. Biochem Biophys Res Commun (2006) 1.17
A tyrosyl-tRNA synthetase adapted to function in group I intron splicing by acquiring a new RNA binding surface. Mol Cell (2005) 1.09
Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol (2008) 1.07
Functional and crystal structure analysis of active site adaptations of a potent anti-angiogenic human tRNA synthetase. Structure (2007) 1.06
Economical parallel protein expression screening and scale-up in Escherichia coli. J Struct Funct Genomics (2006) 1.05
Biochemical characterization of recombinant hepatitis C virus nonstructural protein 4B: evidence for ATP/GTP hydrolysis and adenylate kinase activity. Biochemistry (2009) 1.05
A fully integrated protein crystallization platform for small-molecule drug discovery. J Struct Biol (2003) 1.04
Genes associated with autism spectrum disorder. Brain Res Bull (2012) 1.03
Choline acetyltransferase structure reveals distribution of mutations that cause motor disorders. EMBO J (2004) 1.02
The crystal structure of shikimate dehydrogenase (AroE) reveals a unique NADPH binding mode. J Bacteriol (2003) 1.02
Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. J Med Chem (2010) 1.02
Profiling of membrane protein variants in a baculovirus system by coupling cell-surface detection with small-scale parallel expression. Protein Expr Purif (2007) 1.01
Production of selenomethionyl-derivatized proteins in baculovirus-infected insect cells. Protein Sci (2007) 0.99
High resolution structure of an alternate form of the ferric ion binding protein from Haemophilus influenzae. J Biol Chem (2003) 0.97
Structural basis for iron binding and release by a novel class of periplasmic iron-binding proteins found in gram-negative pathogens. J Bacteriol (2004) 0.95
X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor, FcRn. J Biol Chem (2010) 0.95
Diagnosis and management of skull base osteoradionecrosis after radiotherapy for nasopharyngeal carcinoma. Laryngoscope (2006) 0.95
A copper(I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant. J Med Chem (2008) 0.92
N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding. Protein Sci (2004) 0.92
Removal of harmful cyanobacterial blooms in Taihu Lake using local soils. III. Factors affecting the removal efficiency and an in situ field experiment using chitosan-modified local soils. Environ Pollut (2005) 0.92
Crystal structure of Pasteurella haemolytica ferric ion-binding protein A reveals a novel class of bacterial iron-binding proteins. J Biol Chem (2003) 0.90
Crystal structures of active fully assembled substrate- and product-bound complexes of UDP-N-acetylmuramic acid:L-alanine ligase (MurC) from Haemophilus influenzae. J Bacteriol (2003) 0.89
Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries. J Pharm Biomed Anal (2004) 0.89
Removal of cyanobacterial blooms in Taihu Lake using local soils. I. Equilibrium and kinetic screening on the flocculation of Microcystis aeruginosa using commercially available clays and minerals. Environ Pollut (2005) 0.88
Novel anion-independent iron coordination by members of a third class of bacterial periplasmic ferric ion-binding proteins. J Biol Chem (2004) 0.87
Remedial strategies in structural proteomics: expression, purification, and crystallization of the Vav1/Rac1 complex. Protein Expr Purif (2006) 0.86
Azotobacter vinelandii ferredoxin I: a sequence and structure comparison approach to alteration of [4Fe-4S]2+/+ reduction potential. J Biol Chem (2001) 0.86
A nucleotide binding site in caspase-9 regulates apoptosome activation. Biochemistry (2005) 0.86
Fluorous mixture synthesis of two libraries with hydantoin-, and benzodiazepinedione-fused heterocyclic scaffolds. J Comb Chem (2006) 0.86
Substrate specificity and novel selective inhibitors of TNF-alpha converting enzyme (TACE) from two-dimensional substrate mapping. Comb Chem High Throughput Screen (2005) 0.85
Presence of ferric hydroxide clusters in mutants of Haemophilus influenzae ferric ion-binding protein A. Biochemistry (2003) 0.84
The structure of LpxD from Pseudomonas aeruginosa at 1.3 Å resolution. Acta Crystallogr Sect F Struct Biol Cryst Commun (2011) 0.84
Fragment-based screening for inhibitors of PDE4A using enthalpy arrays and X-ray crystallography. J Biomol Screen (2012) 0.84
Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds. J Med Chem (2012) 0.83
The role of all-trans retinoic acid in bleomycin-induced pulmonary fibrosis in mice. Exp Lung Res (2012) 0.83
A global analysis of tandem 3'UTRs in eosinophilic chronic rhinosinusitis with nasal polyps. PLoS One (2012) 0.83
A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: design and synthesis of benzylpyrazole acylsulfonamides. Bioorg Med Chem (2011) 0.83
Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. J Med Chem (2013) 0.83
Insight into covalent flavinylation and catalysis from redox, spectral, and kinetic analyses of the R474K mutant of the flavoprotein subunit of p-cresol methylhydroxylase. Biochemistry (2004) 0.82
Application of parallel liquid chromatography/mass spectrometry for high throughput microsomal stability screening of compound libraries. J Am Soc Mass Spectrom (2002) 0.82
Studying the cytotoxicity and oxidative stress induced by two kinds of bentonite particles on human B lymphoblast cells in vitro. Chem Biol Interact (2009) 0.82
Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury. Bioorg Med Chem Lett (2011) 0.81
Pesticide poisoning in Zhejiang, China: a retrospective analysis of adult cases registration by occupational disease surveillance and reporting systems from 2006 to 2010. BMJ Open (2013) 0.81
Phosphopeptides enrichment using on-line two-dimensional strong cation exchange followed by reversed-phase liquid chromatography/mass spectrometry. Anal Biochem (2006) 0.81
Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1). Bioorg Med Chem Lett (2013) 0.81
Study of the PDK1/AKT signaling pathway using selective PDK1 inhibitors, HCS, and enhanced biochemical assays. Anal Biochem (2011) 0.80
Investigating DNA damage in tannery workers occupationally exposed to trivalent chromium using comet assay. Mutat Res (2008) 0.80
Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett (2008) 0.80
Protective effect of cerium ion against ultraviolet B radiation-induced water stress in soybean seedlings. Biol Trace Elem Res (2011) 0.80
Comparative structural analysis of a novel glutathioneS-transferase (ATU5508) from Agrobacterium tumefaciens at 2.0 A resolution. Proteins (2006) 0.79
High-throughput mass-directed parallel purification incorporating a multiplexed single quadrupole mass spectrometer. Anal Chem (2002) 0.79
Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors. Bioorg Med Chem Lett (2006) 0.79
Improvement of "hit-to-lead" optimization by integration of in vitro HTS experimental models for early determination of pharmacokinetic properties. Comb Chem High Throughput Screen (2002) 0.79
Cell-based assay for screening 11beta-hydroxysteroid dehydrogenase inhibitors using liquid chromatography/tandem mass spectrometry detection. Rapid Commun Mass Spectrom (2006) 0.79
Interactive curved planar reformation based on snake model. Comput Med Imaging Graph (2008) 0.79
Phenol inhibition and restoration of the bioactivity of anaerobic granular sludge. Appl Biochem Biotechnol (2008) 0.78
Fabrication of silver-coated silica microspheres through mussel-inspired surface functionalization. J Colloid Interface Sci (2011) 0.78
Structure determination of LpxD from the lipopolysaccharide-synthesis pathway of Acinetobacter baumannii. Acta Crystallogr Sect F Struct Biol Cryst Commun (2012) 0.78
Genetic damage and lipid peroxidation in workers occupationally exposed to organic bentonite particles. Mutat Res (2012) 0.78
Crystal structures of transhydrogenase domain I with and without bound NADH. Biochemistry (2002) 0.78
Development of a high-throughput online solid-phase extraction/tandem mass spectrometry method for cytochrome P450 inhibition screening. J Biomol Screen (2010) 0.78
[Association of regulatory region of HLA-DPB1 with nasopharyngeal carcinoma in southern Chinese Hans]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2010) 0.77
Relationship between dispersion and conductivity of polymer nanocomposites: a molecular dynamics study. J Phys Chem B (2012) 0.77